Amantadin AbZ

Quick links

Choose a section

Quick links to important sections

Advertisements

Amantadin AbZ

Advertisements

Overview of Amantadin AbZ

Quick Facts

Property Description
Active ingredient Amantadine Hydrochloride
Form Tablet (oral administration)
Pharmacological class Antiparkinson agent; Anti-influenza virus agent
Common use Modulating certain neurological functions; Interfering with Influenza A virus activity
Origin Synthetic (Adamantane derivative)

Core Composition and Classification

Amantadin AbZ is a prescription medicine formulated as an oral tablet, containing the single active therapeutic ingredient Amantadine Hydrochloride. This core chemical entity is a chemically defined, synthetic substance, belonging to the family of Adamantane derivatives. As a single active ingredient product, Amantadin AbZ delivers the specific therapeutic action of Amantadine. This compound has been clinically recognized for its established effects in the central nervous system and its activity against specific viruses.

Pharmacologically, Amantadine Hydrochloride possesses a unique dual classification, positioning it as both an antiparkinson agent and an anti-influenza virus agent. This duality ensures the substance is classified based on its capability to influence two fundamentally different physiological domains. Amantadin AbZ, as a generic brand, provides this established formulation in a standard tablet form for adults. Its use includes applications in the clinical domain related to certain movement disorders and the ability to act against the Influenza A virus.

General Therapeutic Purpose

The general purpose of Amantadin AbZ is derived from its established mechanisms. As an antiparkinson agent, its function involves helping to modulate neurological functions related to movement by influencing neurotransmitters like dopamine. The specific mechanism involves blocking the M2 ion channel, which is critical for viral replication, thereby establishing its role against the Influenza A virus. This characteristic duality ensures that the medication’s foundational purpose is anchored in both neurological balance and antiviral defense.

Regulatory References

  1. NIH DailyMed Monograph
Advertisements

What side effects are possible with Amantadin AbZ?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Amantadin AbZ, based strictly on government regulatory documents. The risk profile is categorized by frequency and the body system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

The frequency of side effects is officially classified to communicate the likelihood of their occurrence:

  • Common effects documented in regulatory sources include nausea, vomiting, dizziness, insomnia, and dry mouth. Skin effects such as Livedo reticularis (a purplish, lace-like discoloration) and peripheral edema (swelling of the extremities) are also listed in this category.
  • Uncommon reactions may include psychotic reactions and visual disturbances like blurred vision.
  • Rare and Very Rare effects include serious cardiovascular events, such as ventricular fibrillation and seizures, as noted in official prescribing information.

System-Organ Class Groupings and Serious Reactions

Adverse effects are formally grouped by the body system affected. Documented reactions involve the Nervous System (e.g., dizziness, hyperkinesia) and Psychiatric System (e.g., anxiety, confusion, hallucinations, and agitation). Serious adverse reactions explicitly documented in regulatory sources include severe CNS disturbances, such as delirium and psychotic states, and life-threatening Cardiac Arrhythmias.

Population-Specific Safety Considerations

Official safety statements note specific considerations for certain patient groups. Older adults may exhibit increased sensitivity to Central Nervous System effects, such as confusion. For individuals with renal impairment, the risk of drug accumulation and toxicity is increased, and severe renal impairment is listed as a safety restriction.

Time-Related Safety Patterns

Regulatory documentation notes that CNS side effects are often more frequent at the start of treatment or following dose increases. The risk of Neuroleptic Malignant Syndrome is officially associated with the abrupt cessation or rapid reduction of the medication.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Acute poisoning with Amantadine Hydrochloride is officially documented to involve severe toxicity affecting the central nervous system (CNS) and the cardiovascular system. Documented clinical manifestations of overdose include CNS excitation presenting as acute psychosis, visual hallucinations, disorientation, and hyperreflexia, which may progress to convulsions (seizures) or a depressed level of consciousness like coma. Cardiovascular instability is marked by arrhythmias, sinus tachycardia, and the risk of sudden cardiac death or ventricular arrhythmias due to disturbances such as QT prolongation.

Emergency Actions and Management

Regulatory documents state that an individual must seek immediate medical attention upon suspicion of overdose given the potential for these life-threatening events. No specific antidote is known for Amantadine poisoning. Management protocols, as described in official labeling, consist of symptomatic and supportive treatment, with continuous ECG monitoring required due to the high risk of critical cardiac instability and QRS/QT interval changes. Procedures may include treating complications such as status epilepticus, hyperthermia, and maintaining a patent airway.

Vulnerable Populations

Official labeling notes that the risk of severe intoxication is particularly heightened in patients with renal impairment and the elderly. This is a documented pharmacokinetic consideration, as the drug is primarily eliminated by the kidneys, and compromised function can lead to drug accumulation even when therapeutic doses are administered.

Advertisements

Therapeutic Uses of Amantadin AbZ

What Amantadin AbZ Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed in situations involving certain distressing symptoms. Amantadin AbZ is commonly used to help manage symptoms related to Parkinson's disease, including complications like levodopa-induced dyskinesia, and is applied in contexts involving the acute systemic symptoms of Influenza A virus infection.

In the context of movement disorders, the medication is relevant in clinical settings that involve chronic or disruptive symptom patterns, such as rigidity and slowness of movement. This provides supportive relief when core motor symptoms are more noticeable. It contributes to improved comfort during symptomatic periods, supporting a more manageable sense of stability.

The medication is also relevant for managing symptoms that create noticeable physiological strain associated with acute viral episodes.

“This therapeutic support may help address symptom clusters that may become intense, potentially helping to reduce the overall symptom load associated with the illness.”


Quick Fact: Symptomatic Focus

Domain Primary Symptom Focus General Benefit
Neurological Stiffness, slowness, involuntary movements Supports comfort and functional stability
Antiviral Fever, malaise, acute systemic discomfort May help ease overall symptom load during illness

Regulatory References

  1. NIH MedlinePlus overview of Amantadine uses
Advertisements

Eligibility and Restrictions for Use

Eligibility Profile for Amantadin AbZ

Official regulatory documents define strict population eligibility criteria for the use of Amantadin AbZ (Amantadine Hydrochloride).


Who Must Not Use This Medicine (Contraindications)

Use is strictly contraindicated for patients with hypersensitivity to the medicine, untreated angle-closure glaucoma, End-Stage Renal Disease (ESRD), refractory epilepsy, or conditions that subject an individual to convulsions. The medicine is also contraindicated during pregnancy and for nursing mothers; women of child-bearing potential must use effective contraception.


Populations Requiring Conditional Use

Use is restricted or requires special caution for several groups. Patients with non-severe renal impairment require a dose reduction based on kidney function. Special caution applies to individuals with liver disorders, a history of congestive heart failure or cardiac arrhythmias, and those with underlying psychiatric disorders. Older adults must use the lowest effective dose, with their therapy dependent on established renal function.


Age-Group Eligibility

The medicine has established use for adults and children aged 1 to 15 years for labeled indications. Safety and efficacy are not established for infants under one year of age.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Amantadin AbZ highlights clinically significant interactions rooted in the drug's primary clearance pathway. Co-administration with certain combination diuretics (e.g., Triamterene/Hydrochlorothiazide) or with Trimethoprim may cause an increase in Amantadine's plasma concentration. This pharmacokinetic interaction occurs because these substances inhibit or compete for the renal tubular secretion process, leading to a substantial reduction in Amantadine elimination and resulting accumulation. Changes in urine acidity are also noted: alkalinizing agents may similarly decrease Amantadine elimination.

The label also describes several pharmacodynamic interactions resulting in additive effects. When used concurrently with other Central Nervous System (CNS) active medications, Levodopa, or anticholinergic agents, there is a documented potential for the reinforcement of neurological effects, such as heightened confusion or hallucinations. The consumption of alcohol is not recommended due to the potential for additive CNS toxicity, including dizziness and disorientation.

A specific co-administration restriction applies to certain vaccines. Amantadin AbZ is not recommended for concurrent use with Live Attenuated Influenza Vaccines (LAIV) due to the official constraint related to potential impact on vaccine efficacy. Furthermore, because Amantadine is primarily renally cleared, the medication is officially contraindicated in individuals with End-Stage Renal Disease, where the exposure to the drug is highly increased.

Advertisements

Mechanism of Action

Modulation of Central Nervous System (CNS) Signaling Balance

Amantadine possesses two entirely distinct pharmacodynamic mechanisms, operating on both the neurological system and the viral replication cycle. The drug functions primarily by targeting the balance between excitation and inhibition in the brain's motor circuits. Amantadine acts as an antagonist of the excitatory NMDA glutamate receptor while simultaneously potentiating the inhibitory dopaminergic system by increasing dopamine release. This dual molecular action results in the modulation of neural pathway activity, leading to an adjustment of motor circuit output.

Inhibition of Viral Uncoating and Replication

The second, separate mechanism targets the Influenza A virus M2 protein, a crucial proton channel embedded in the viral envelope. Amantadine physically blocks this channel, inhibiting the necessary influx of protons (H^+) that would otherwise acidify the viral core. This functional blockade interrupts the viral replication cascade by interfering with the necessary process of nucleic acid release into the host cell cytoplasm.

Mechanism Limitations and Specificity

The antiviral mechanism is highly specific to the structure of the Influenza A M2 protein, rendering it ineffective against other viruses. The mechanism is constrained by the rapid emergence of viral resistance, which occurs when mutations in the M2 protein prevent drug binding, functionally overriding the channel blockade mechanism.

Advertisements

Dosage and Administration Information

How to Use Amantadin AbZ

The use of Amantadin AbZ, an immediate-release form of Amantadine Hydrochloride, follows standardized administration and dosing schedules. The medication is designated for the oral route only, and the tablets or capsules are typically swallowed whole with water. It is generally recommended that the dose be administered with food (e.g., at mealtimes) to support proper intake and mitigate gastric discomfort.

The regimen for neurological applications, such as in Parkinson's disease, typically begins with an initial dose of 100 mg daily. This is often increased after one week to the standard maintenance dose of 200 mg per day, usually given in two divided doses. Doses that exceed this level, up to a maximum of 400 mg daily, are increased gradually in small increments (e.g., 100 mg) at intervals of no less than one week.

Usage for the management of acute systemic symptoms related to the Influenza A virus is generally prescribed as 200 mg per day, taken either as a single dose or divided twice daily. This therapeutic course is defined as a short-term regimen, continuing for approximately four to five days, or for 24 to 48 hours after symptoms have resolved.

Specific dose modifications are applied for certain patient groups. Older adults (65 years and over) typically require a maximum daily dose of 100 mg. Dosage in patients with impaired renal function is adjusted based on the patient's estimated Creatinine Clearance, often requiring a reduced dose or an extended dosing interval. The medicine must not be stopped abruptly; instead, a gradual withdrawal (tapering) is a necessary procedural step to conclude the treatment.

Advertisements

Recent Clinical Evidence

Amantadin AbZ: Recent Clinical Evidence

Evidence for Symptomatic Management of Parkinson's Disease

Research has explored Amantadin AbZ and what was observed in conditions marked by functional limitations, such as stiffness and slowness of movement. The evidence base includes Randomized Controlled Trials (RCTs) that research examined how symptoms change over defined short-term periods. Studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort; follow-up durations were typically short-term (four to sixteen weeks).

When studies explored the medication as the sole treatment, evidence is limited and the evidence level was observed in some studies to be Low. When the medicine was evaluated in combination with other standard Parkinson's treatments, evidence contributes to understanding symptom patterns; the evidence level was observed in some studies to be Moderate.

Sub-Study Focus: Evidence for Levodopa-Induced Dyskinesia

The medication was studied for use in people with advanced Parkinson's disease who experience involuntary movements, or dyskinesia, often linked to their levodopa treatment. The research primarily relied on Randomized, double-blind, placebo-controlled trials which examined outcomes capturing phases of heightened symptom activity. Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes in involuntary movements over intermediate-term follow-up periods, such as those lasting up to eight months.

Evidence for Acute Symptoms of Influenza A Virus Infection

Amantadin AbZ was evaluated in studies related to acute symptoms of Influenza A. This research explored the medication was studied for use in conditions associated with acute or disruptive episodes, where outcomes related to systemic or functional imbalance were measured. The research included RCTs comparing the medicine against placebo or other agents. Findings describe patterns observed in the studies related to research exploring short-term symptom changes, especially when outcomes related to episodic or acute changes were monitored in healthy adults.

Long-Term Studies and Durability of Follow-up

Research examined the long-term experience of people using Amantadin AbZ, but the evidence base for long-term effects is limited. Most controlled trials have follow-up durations that were limited to short or intermediate periods of a few months. Long-term effects are not fully established by controlled study data.

What Is Still Uncertain About Amantadin AbZ Research

Research describes limitations, including that long-term effects are not fully established through extensive controlled research. For the neurological applications, many older studies had sample sizes that were modest, and findings were mixed across some of the primary trials. Evidence consistency varies across studies for groups like the elderly and pediatric populations in the antiviral context, and comparative evidence is lacking against current standard-of-care treatments in recent high-quality studies.

Key Studies & References Parkinson's disease: diagnosis and management (NICE Guideline NG71)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Amantadin AbZ (FAQ)


Q: Is Amantadin AbZ the same as Symmetrel?

Amantadin AbZ is a generic medicine that contains the active ingredient Amantadine Hydrochloride. Symmetrel is one of the original brand names under which this exact active ingredient was previously sold. Both medicines contain the same pharmaceutical compound used for the same therapeutic purposes.


Q: What happens if I forget to take a dose of Amantadin AbZ?

Official patient information for the immediate-release form of this medication generally recommends skipping the missed dose entirely. The next scheduled dose is typically continued at the regular time. This approach is recommended in official guidelines to manage the risk of increased exposure or side effects due to drug accumulation.


Q: Are there any major foods or drinks to avoid while taking this medicine?

Regulatory information notes that co-administration with alcohol is not recommended due to the potential for heightened Central Nervous System (CNS) side effects, such as dizziness. While specific foods are not usually restricted, the medicine can interact with substances that affect the body’s acidity, which influences how it is eliminated.


Q: Can women who are pregnant or breastfeeding use Amantadin AbZ?

Official regulatory documents strictly prohibit the use of Amantadin AbZ during pregnancy and for women who are nursing. The medicine is known to pass into breast milk, and its use is prohibited due to regulatory constraints related to pregnancy and lactation.


Q: What is the official stance on Amantadin AbZ for treating fatigue?

The official regulatory approvals for Amantadin AbZ are limited to the management of Parkinson’s disease symptoms and for treating or preventing Influenza A virus infection. Official documentation does not list the treatment of general fatigue as an approved indication.


Q: Is there a known link between Amantadin AbZ and Livedo Reticularis?

Yes, Livedo reticularis is a documented side effect, often listed as common in official product information. This condition is a skin reaction described as a purplish, lace-like discoloration that typically appears on the arms and legs.


Q: Does Amantadin AbZ interact with supplements or vitamins?

Regulatory sources advise caution because Amantadin AbZ can interact with other Central Nervous System active agents and with substances that affect the kidneys or change urine acidity. It is generally understood that a healthcare provider must be informed about all concurrent medications, vitamins, and supplements being taken.


Q: Can Amantadin AbZ cause swelling (edema) in the legs or ankles?

Yes, peripheral edema, which is swelling of the extremities, is noted in regulatory documents as a common side effect of Amantadin AbZ. This side effect often presents as noticeable swelling in the legs or ankles.


Q: Is it necessary to take Amantadin AbZ with food?

Official prescribing guidelines generally recommend taking the immediate-release tablets with food, such as at mealtimes. This instruction is primarily given to help minimize the possibility of gastric discomfort or stomach upset.


Q: Are there different forms of Amantadin AbZ (e.g., tablet, liquid)?

Amantadine Hydrochloride, the active ingredient, is manufactured in various regulatory forms, including tablets, capsules, and oral solutions (syrup). Amantadin AbZ specifically is sold as an immediate-release tablet formulation.


Q: How quickly can someone expect to feel the effects of Amantadin AbZ?

Official product information indicates that for some conditions, the effects of Amantadin AbZ may begin to be noticeable within a few days of starting treatment. However, the observed time for a full therapeutic response may vary among individuals.


Q: Does Amantadin AbZ build up in the body over time?

Yes, Amantadine is eliminated slowly and primarily unchanged by the kidneys. The drug can accumulate significantly, particularly in older adults or those with reduced kidney function, which is a key factor in how dosing is determined.


Q: What is the difference between Amantadine and other similar Parkinson's treatments?

Amantadine has a unique dual pharmacological classification and mechanism of action. It works by blocking the NMDA receptor and enhancing the dopaminergic system. Other treatments for Parkinson's disease typically work through different chemical pathways, such as replacing dopamine or acting as selective agonists.


Q: Can I take pain relievers like ibuprofen or acetaminophen with Amantadin AbZ?

Official drug labels do not list common over-the-counter medicines like ibuprofen or acetaminophen as specific contraindications. However, interactions with pain relievers that affect kidney function or the central nervous system are possible. Compatibility with other medicines is typically confirmed by a healthcare provider.


Q: How long does the effect of one dose of Amantadin AbZ typically last?

The duration of the medication's effect is related to its elimination half-life, which is approximately 15 hours in healthy individuals. This extended elimination time is factored into the official dosing schedules, such as the typical twice-daily administration.


Q: Is there any research on Amantadin AbZ and cognitive function?

The research base for Amantadine primarily focuses on motor symptoms, but studies have been conducted to evaluate its potential impact on specific measures of cognitive function. Research is ongoing to better understand its full range of effects, including non-motor symptoms.


Q: What if I have an allergic reaction to Amantadin AbZ?

Amantadin AbZ is strictly contraindicated in anyone with a known hypersensitivity (allergic reaction) to the drug. If signs of a severe allergic reaction occur, such as trouble breathing, hives, or swelling of the face, official documentation notes that immediate medical attention is necessary.


Q: Do I need regular blood tests while taking Amantadin AbZ?

While not always routine, official product information advises that rare changes in blood cell counts have been reported. Depending on the patient's underlying conditions, monitoring through regular blood tests or liver function tests may also be considered by a physician for some patients.


Q: What is the maximum recommended duration for Amantadin AbZ use?

For its antiviral use against Influenza A, the duration is clearly defined as short-term (typically 3 to 5 days). For its neurological applications, the medication is often used long-term, but controlled clinical studies often have limited follow-up duration, and long-term effects have not been fully established by comprehensive controlled research.


Q: What does research evidence say about Amantadin AbZ for tremors?

Research has primarily examined Amantadine for other movement symptoms of Parkinson’s disease, such as stiffness, slowness, and involuntary movements (dyskinesia). While some older data exists, the evidence base specifically for reducing the severity of parkinsonian tremor is often described as limited.

Advertisements

How should Amantadin AbZ be stored and disposed of?

Storage and Protection Requirements

Amantadine Hydrochloride tablets must be stored at Controlled Room Temperature (CRT), specifically defined as 20^circC to 25^circC (68^circF to 77^circF). To ensure product stability until the expiration date, the medicine must be protected from light and excess moisture.

Containers must be kept tightly closed and stored in the original container with a child-resistant closure. It is officially required to keep this medication out of the sight and reach of children.


Official Disposal Rules

Unused or expired Amantadine Hydrochloride tablets must not be flushed down a toilet or thrown into general wastewater. The preferred disposal method is to use a community drug take-back program.

If a take-back program is unavailable, the product should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag or container, and then discarded in the household trash, according to FDA recommendations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amantadin AbZ found in:

A-Z Index: